In late 2020 a converted van appeared in central Glasgow. Inside were clean needles, sterilising equipment, mirrors, sharps bins for the disposal of syringes, and supplies of the overdose reversal drug naloxone. There were also boxes containing protein bars, tea, blankets and a defibrillator, as well as two chairs and tables where injections could be prepared.
The van had been converted, and was being driven, by Peter Krykant – a former outreach worker with his own history of homelessness and injecting drug use. Frustrated by the fact that no overdose prevention centre (OPC) had yet opened in the city despite calls from the local NHS, he took the law into his own hands and, after a successful crowdfunding campaign, opened one independently.
OPCs are places where people can take illegally purchased drugs in a supervised environment, using clean equipment and with staff able to intervene in the case of an overdose. The first such centre opened in the Swiss capital, Bern, in 1986, and there are now around 200 across the world from Berlin, Paris and Geneva to Sydney, Vancouver and New York.
While the centres go under an array of different names including “drug consumption rooms”, “safer consumption sites” and “safe injecting facilities”, the essential concept – providing a safe environment for the use of risky, illegal drugs – remains the same. There have been no recorded overdose deaths at any of these centres since the first opened 36 years ago.
No such services exist in the UK, however. As drug-related deaths continue to rise the debate over whether this should change has become increasingly heated – especially in Scotland, where drug mortality rates are the highest in Europe. The largest outbreak of HIV in the UK in over 30 years has been among people who inject drugs in Glasgow, Scotland’s largest city, and is ongoing.
Krykant’s unsanctioned Glasgow OPC operated for nine months. It oversaw 894 injection events involving heroin and cocaine and treated nine potentially fatal overdoses. Krykant describes its impact as “overwhelming”. “I saw people move from groin injecting to injecting in less dangerous areas [of the body] due to having a warm and well-lit environment where they could take their time and not feel rushed,” he says. “Myself and the other volunteers who helped run the service witnessed people feeling cared about for the first time. The service turned into a beacon of safety for many. We started supplying basic things like warm clothing, drinks and sanitary products. On one occasion we bought a wheelchair for a person who had lost a leg.”
The Glasgow police largely tolerated the facility, although on one occasion Krykant was cautioned for refusing to let officers into the van while it was being used. And the media were fascinated: during its brief time of operation, reports about the van appeared in UK and international media including the New York Times.
Due to health issues, Krykant reluctantly closed the facility in the summer of 2021. The van was donated to the Transform Drug Policy Foundation and now tours the UK, demonstrating what an OPC would look like in practice. Krykant believes it served a vital purpose in demonstrating that “it could be possible to set up and run OPCs within current frameworks”. He is still hopeful that a formal facility will be commissioned in the near future, but the UK government remains opposed.
Pat Hudson is an emeritus professor of history at Cardiff University. In 2017 her son Kevin was found dead in a locked toilet in a department store in the Welsh town of Carmarthen. He was 32 and an experienced tree surgeon.
Kevin Hudson died of cardiac arrest and brain damage after injecting heroin. He had been battling addiction and was making progress, but died alone after the kind of accidental overdose that kills thousands in the UK every year. His mother said: “If Kevin had had somewhere safe to go in the town to inject, without fear of criminalisation or stigma and with a medically qualified person in attendance, he would certainly not have locked himself in a toilet where no one could reach him.”
Pat Hudson, a member of the campaign group Anyone’s Child: Families for Safer Drug Control, is calling for OPCs to be introduced as a way of providing life-saving support. While first and foremost about saving lives, she says this is also about “providing medical and addiction advice for those seeking help”.
OPCs have been found to successfully reduce the risk of blood-borne virus transmission, direct clients to treatment services, provide advice on safer consumption, and reduce levels of public injecting and discarded needles. By creating a non-stigmatising environment, they can also attract people who might otherwise not come into contact with support services, or who previously had unhappy experiences in treatment.
More than 300,000 people are thought to use opiates or crack cocaine regularly in England, of whom about half are in treatment. But even for those accessing such services, treatment can only help if they are kept safe and alive when they are using. For people such as Kevin Hudson, a lack of safe drug consumption spaces significantly increases the risk of death.
In December 2021, in response to record levels of drug-related deaths, the UK government committed £780m to improving treatment services in England and Wales – money that was desperately needed following years of disinvestment. But despite organisations such as the harm reduction charity Cranstoun signalling their intention to open OPCs when conditions allow, there are no plans to pilot such facilities in the UK government’s ten-year drug strategy for England.
The UN’s International Narcotics Control Board has said that OPCs are consistent with international drug control treaties, as long as they are part of a wider system of drug treatment. Under UK law, however, allowing the preparation of illicitly purchased drugs for ingestion could be construed as illegal.
This means that anyone operating an OPC could potentially be liable for prosecution. In 2016 Scotland’s largest NHS organisation, Greater Glasgow and Clyde, recommended that an OPC be opened in Glasgow city centre in response to the high rates of drug-related deaths and the emergence of the HIV outbreak, highlighting “widespread support [among] stakeholders from the target population, health services, and organisations representing drug users and their families”.
The lord advocate, Scotland’s chief public prosecutor, was asked to produce a “letter of comfort” to guarantee such facilities would not be subject to prosecution. This proposal was not successful and the current lord advocate has said that she cannot make an activity unlawful, nor grant immunity from prosecution. However, in 2021 she said she “would be prepared to consider any such future proposal, but it would have to be specific and underpinned by evidence, and it would require fresh consideration”.
In September 2021 the Scottish Drug Deaths Taskforce asked the Scottish government to “explore all options within the existing legal framework” that would enable OPCs to be piloted. Many Scottish MPs and MSPs have also called for action, with a private members’ bill currently being put through the Scottish Parliament. And in January 2022 the UK Faculty of Public Health published a letter signed by every royal medical college calling on the UK government to “take steps towards funding [OPC] pilots … to save lives and reduce harm”. Angela Constance, Scotland’s minister for drug policy, confirmed in June 2022 that a new proposal had been submitted for consideration by the Crown Office.
The UK government’s consistent refusal to introduce legal reforms to protect OPC providers from the threat of criminal sanctions has set Westminster against the Scottish government, which views OPCs as an important tool in its broader public health-led response to drug harms.
Recognising that a policy change in Westminster looks unlikely in the short term, Constance has said the Scottish government is “leaving no stone unturned to deliver clinically and legally safe consumption facilities”. In contrast, according to Pat Hudson, the UK government is “digging its heels in” because OPCs are seen as condoning illegal drug use.
Insite was the first sanctioned and supervised injecting site to open in North America. Founded in 2003, it operates in the Downtown Eastside neighbourhood of Vancouver, a city that for decades has had high levels of homelessness, street injecting and drug-related deaths.
The Insite facility provides booths, each with a table, mirror and waste bin. According to 2019 data, there is space for more than 300 injections a day. People need not be registered and there are no forms to fill in on arrival. In almost two decades there have been thousands of overdose events but no fatalities.
Insite also offers a key source of evidence on the effectiveness and impact of OPCs. A 2011 study published in the Lancet found that, in the two years after Insite opened, the rate of overdose deaths within 500m of the facility fell by 35 per cent, compared with 9 per cent in the rest of Vancouver. More recently, a six-year cohort study found that people who used Insite and other OPCs in Vancouver at least weekly were almost 50 per cent less likely to die of any cause during the time of the study than other people regularly using drugs.
Evidence from Insite and other established OPCs shows that these centres reduce risky activities such as needle sharing while increasing engagement with health and treatment services. This led the UK government’s Advisory Council on the Misuse of Drugs to call for them to be considered in 2016.
Similarly, a 2019 review of global evidence commissioned by Public Health England found that OPCs were effective in reducing high-risk injecting behaviours, drug-related litter and ambulance call-outs, while increasing access to education and other forms of social support. This review also confirmed there was no evidence of increased crime in the vicinity of OPCs.
Over a six-month period, our research team spoke to senior figures across Scotland – from government and the criminal justice system to local health and social care teams and charities – to explore their views on OPCs and what they saw as barriers to adoption. We also spoke to family members of people who use drugs, most of whom were overwhelmingly supportive. Many suggested that OPCs could provide a lifeline where other interventions had failed – and above all, “hope, just absolute and utter hope” that their loved ones could be kept safe when facing their most difficult and dangerous moments.
Many were bewildered as to why OPCs had not been introduced already. One family member described a “lightbulb moment” when she found herself thinking: “I can’t believe we don’t do this as a humane society.” Another asked: “Why would we not want to keep everybody safe?”
As well as recognising the lifesaving potential of OPCs, local decision-makers highlighted their value in reducing levels of public injecting and discarded needles – often the main concern for the general public who, as one respondent put it, just “want rid” of drug problems in their area. Among decision-makers and family members alike, OPCs represented a compassionate, non-judgemental approach to drug issues. They mattered not only because they could save lives, but because they stood for an alternative response to drug problems more broadly.
In June 2022 Alexis Goosdeel, director of the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA), the EU’s leading illicit drugs authority, described OPCs as “key instruments” in reducing drug harms. Goosdeel’s comments reflect a broad consensus within the drug research community, but this view is not shared by everybody.
The UK government argues that evidence of the effectiveness of OPCs is not sufficient to justify their introduction. In part, as one major review noted in 2018, this is because “estimating the overall effect of [OPCs] on fatal and nonfatal overdoses is difficult”.
Preventing individual deaths does not automatically mean overall drug mortality rates will be reduced. Someone who has had an overdose reversed in an OPC may still suffer a fatal overdose later somewhere else, and OPCs often operate alongside other services such as the provision of take-home naloxone and drug treatment services such as methadone, which significantly reduce death rates.
A recent review of an OPC in Melbourne estimated that, of the 271 “extremely serious overdoses” that were treated in its first two years of operation, between 21 and 27 deaths were avoided. But again it is difficult to isolate the impact on drug deaths from other factors; some have argued that a “heroin drought” skewed initial results from Sydney’s Medically Supervised Injecting Centre.
OPCs are not amenable to the kind of randomised control trials that might be expected for other medical interventions. However, as a recent Lancet commentary pointed out, many public health interventions have been introduced without such trials.
We found that local decision-makers were more pragmatic and wanted mainly to know whether OPCs were cost-effective compared to other interventions. While recognising that “politically the evidence would need to be extremely strong” to get the green light, most felt such evidence was already available from other countries and could be developed further through local pilots.
Anyone hoping to develop local evidence faces a Catch-22, however. Building evidence requires opening an OPC – yet this is blocked by the UK government on the grounds that the available evidence is insufficient. Without the reassurance of central government support or formal agreements with local police, many local authorities and service providers lack the confidence to go ahead.
Among the family members we interviewed OPCs were attractive not only because of the evidence that they save lives, but because they represented new hope and the promise of greater dignity for their loved ones.
Communities affected by visible public drug consumption, however, often have different priorities. As a number of our participants pointed out, OPCs also need the support of the wider community if they are to be successful.
In the past, community support for OPCs has been strongest when large-scale drug scenes – such as emerged in parts of Germany and Switzerland in the 1980s and in Sydney in the 1990s – became a pressing social problem. More recently the rise in UK drug deaths has raised the political pressure for action. However, public concern over visible drug consumption, especially when many people find it threatening or morally wrong, does not necessarily translate into support for OPCs.
A US survey found that many people believed money spent on OPCs would be better allocated to more conventional treatment and recovery programmes. Some community groups have expressed concern that OPCs would create a “honeypot effect”, not only attracting people using drugs but also dealers to the vicinity. Other research suggests that if people hear about the experiences of people who use OPCs (or their families), rather than just being presented with statistics and data, then support increases. In areas such as Sydney, where OPCs have operated for decades, studies have found high levels of public support and perceived reductions in problems such as discarded needles.
In a recent UK-wide poll, just under half the respondents supported OPCs and only 18 per cent opposed them. Yet for some sceptics, the basic principle of facilitating drug consumption is wrong, especially without a clear requirement that those using the service take steps towards recovery.
When Boris Johnson was prime minister the UK’s Conservative government argued that OPCs ran counter to its “tough” approach to drugs – not only enabling but even “encouraging” use (a claim not supported by any available evidence). Because it is much easier not to open an OPC, political inertia and institutional risk-aversion are always liable to prevent innovation.
Settling these controversies is about more than just appealing to evidence. Recent research has confirmed what, to a casual observer, may seem obvious: even what you call these centres makes a difference. The label “drug consumption room”, for example, garners less public support than “overdose prevention centre” because one sounds like a facility designed to enable drug use to take place while the other frames it as saving lives. Getting public clarity on what OPCs actually do is therefore critical.
That OPCs save individual lives is beyond dispute. But they do so by accepting that creating safer environments for otherwise high-risk forms of drug consumption can be the right thing to do. For some people, that will never be an acceptable principle – and the high level of stigmatisation towards those who inject drugs only serves to reinforce this view. For many others, however, it sits at the heart of a compassionate and effective approach to reducing drug harms.
While every participant in our research supported piloting OPCs in principle, almost all decision-makers felt the power to give the green light lay elsewhere. In Scotland the issue is seen to have “been kicked around like a political football” while the UK government insists that OPCs are a distraction from other treatment responses and claims that advocates view them as a kind of “silver bullet” (something our participants strongly disputed).
Despite many expert voices arguing that, after more than 50 years, a review of the UK’s primary drug legislation, the 1971 Misuse of Drugs Act, is urgently needed, it seems unlikely that this act will be amended in the short term at least. However, senior police authorities (such as regional police and crime commissioners in England) could agree to memorandums of understanding guaranteeing that local police will not enforce the act in ways that prevent OPCs from operating. This would be possible without any change to primary legislation but relies on senior local leaders championing their case.
There is certainly growing support for OPCs in English regions such as the West Midlands that have pressing drug problems. Should regional police forces arrive at agreements to allow local adoption, there are organisations ready to create facilities.
OPCs can only ever be one part of society’s response to drug dependency and harm, but without the opportunity to pilot them in the UK it will never be possible to assess what the scale of that contribution could be, or how many lives would be saved. In the face of a growing drug death crisis, the need for action is more urgent than ever.